ARTICLE | Management Tracks
WuXi vet Yao joins Allogene Overland as CEO; plus uniQure, Merck, Exelixis and Pharming
June 21, 2021 6:44 PM UTC
Allogene Overland Biopharm, a joint venture between Overland Pharmaceuticals and Allogene Therapeutics Inc. (NASDAQ:ALLO) focused on bringing allogeneic cell therapies to China, named Shuyuan Yao CEO. Yao was CSO, head of research and technology development of advanced therapies at WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359).
uniQure N.V. (NASDAQ:QURE) promoted Christian Klemt from chief accounting officer to CFO and principal financial officer. Klemt, who will also continue to serve as general manager of the gene therapy company’s Amsterdam site, succeeds Matthew Kapusta, who will continue in his role as CEO. ...